H&S Biolab
H&S Biolab develops urine-based biomarker technologies and digital healthcare platforms to enable earlier, more accurate diagnosis of kidney function and other diseases. The company combines multi-omics, in-vitro diagnostic kits, and IT convergence—including big data, AI, and machine learning—to deliver point-of-care and personalized diagnostic solutions. Its offerings include on-site diagnostic kits and a digital health SaaS/platform for data-driven interpretation and clinical decision support. Business models include SaaS, licensing, and platform technology partnerships with healthcare companies and diagnostic labs. H&S Biolab targets global in-vitro diagnostic and digital health markets focused on chronic disease management, oncology, and infectious and rare diseases.
H&S Biolab
H&S Biolab develops urine-based biomarker technologies and digital healthcare platforms to enable earlier, more accurate diagnosis of kidney function and other diseases. The company combines multi-omics, in-vitro diagnostic kits, and IT convergence—including big data, AI, and machine learning—to deliver point-of-care and personalized diagnostic solutions. Its offerings include on-site diagnostic kits and a digital health SaaS/platform for data-driven interpretation and clinical decision support. Business models include SaaS, licensing, and platform technology partnerships with healthcare companies and diagnostic labs. H&S Biolab targets global in-vitro diagnostic and digital health markets focused on chronic disease management, oncology, and infectious and rare diseases.